Roche

News

Roche's Tecentriq gains new first-line lung cancer use

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients.

News

Roche's TIGIT drug shows promise in untreated lung cancer

Roche has announced positive first phase 2 results from its new kind of cancer immunotherapy, showing that adding tiragolumab to its already approved Tecentriq creates a more potent combina

News

Merck & Co squares up to Roche with Keytruda data in triple-...

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good

News

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.

Market Access

NICE backs NHS funding for Roche's Kadcyla in early breast c...

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people with HER2-positive early breast can

News

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results.

Roche's Tecentriq gains new first-line lung cancer use

Roche's TIGIT drug shows promise in untreated lung cancer

Merck & Co squares up to Roche with Keytruda data in triple-...

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE backs NHS funding for Roche's Kadcyla in early breast c...

Sanofi and Regeneron eye challenge to Merck & Co in first li...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks